Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have received an average rating of “Moderate Buy” from the twenty-three analysts that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $100.27.

Several research firms have weighed in on EW. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Truist Financial increased their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th.

Edwards Lifesciences Trading Up 0.0%

Shares of NYSE:EW opened at $85.23 on Friday. The company’s 50-day moving average price is $88.66 and its two-hundred day moving average price is $86.07. Edwards Lifesciences has a one year low of $72.30 and a one year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The stock has a market capitalization of $49.08 billion, a PE ratio of 48.98, a price-to-earnings-growth ratio of 2.23 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts forecast that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,045 shares of company stock worth $455,341 over the last quarter. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences during the 2nd quarter worth $1,274,082,000. Norges Bank acquired a new position in Edwards Lifesciences in the 4th quarter valued at $803,686,000. Bank of America Corp DE acquired a new position in Edwards Lifesciences in the 2nd quarter valued at $605,397,000. Finally, Deutsche Bank AG acquired a new position in Edwards Lifesciences in the 2nd quarter valued at $516,552,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.